Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–9 of 9 results
Advanced filters: Author: Shensi Shen Clear advanced filters

  • Drug-tolerant persister (DTP) cells are a rare subpopulation of cancer cells that can survive chemotherapy through reversible non-genetic mechanisms. Here, the authors provide their perspective on the existing gaps and outline the research paths still required to bridge basic DTP research with effective clinical strategies.

    • Zhile Wang
    • Mengyao Wang
    • Shensi Shen
    ReviewsOpen Access
    Nature Communications
    Volume: 16, P: 1-12

  • Melanoma persister cells are tolerant to anti-BRAF and anti-MEK inhibition and can trigger cancer relapse. Here the authors show that a subset of N6-methyladenosine modified mRNAs is translationally activated in persister cells. This preferential translation can be abrogated via eIF4A inhibition.

    • Shensi Shen
    • Sara Faouzi
    • Caroline Robert
    ResearchOpen Access
    Nature Communications
    Volume: 10, P: 1-14

  • Polysulfide-iodide redox flow batteries attract great attention, while restricting by the limited energy efficiency and power density. Here, authors introduce single Co atoms into the defective MoS2, endowing a fast transformation of S2−/Sx 2− and I−/I3 −, thus leading to good battery performance.

    • Zhigui Wang
    • Guolong Lu
    • Xijun Liu
    ResearchOpen Access
    Nature Communications
    Volume: 16, P: 1-11

  • Resistance to therapy remains the biggest challenge to achieving cures in patients with cancer. In this Roadmap, Russo et al. overview the field of cancer drug-tolerant persister cells providing paths to advance our understanding of their biology with innovative technologies and recommend strategies to therapeutically target them to ensure that more prolonged responses are achieved in patients with cancer.

    • Mariangela Russo
    • Mengnuo Chen
    • Alberto Bardelli
    Reviews
    Nature Reviews Cancer
    Volume: 24, P: 694-717

  • Despite improved effectiveness, most systemic cancer therapies are not curative and most patients will develop acquired resistance that often cannot be explained by the emergence of specific genomic alterations. In this Perspective, the authors describe the potential role of a small population of tumour cells, termed drug-tolerant persister cells, that are able to survive therapy and, on continued treatment exposure, develop stable mechanisms of resistance to systemic therapies.

    • Yi Pu
    • Lu Li
    • Shensi Shen
    Reviews
    Nature Reviews Clinical Oncology
    Volume: 20, P: 799-813

  • A high serum lactate dehydrogenase (LDH) level is generally associated with an inferior outcome in patients with most tumour types. LDH is also known to have immunosuppressive and/or tumour-promoting effects, suggesting a potentially broader role for this enzyme in clinical oncology. In this Review, the authors provide a holistic overview of the current role of LDH in both cancer biology and oncology, and highlight possible areas of future research interest, including the development of novel therapies targeting LDH.

    • Giuseppina Claps
    • Sara Faouzi
    • Caroline Robert
    Reviews
    Nature Reviews Clinical Oncology
    Volume: 19, P: 749-762